StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research report released on Monday morning. The brokerage issued a sell rating on the stock.

Several other analysts have also recently commented on the stock. Stephens reissued an equal weight rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a report on Friday, June 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Hold and a consensus target price of $55.65.

Catalent Price Performance

Shares of Catalent stock opened at $58.07 on Monday. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The stock has a market capitalization of $10.51 billion, a price-to-earnings ratio of -9.52, a P/E/G ratio of 2.36 and a beta of 1.16. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20. The firm’s 50-day moving average price is $55.72 and its two-hundred day moving average price is $54.68.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. On average, equities analysts predict that Catalent will post -0.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the transaction, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Lindbrook Capital LLC lifted its stake in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Catalent in the 3rd quarter worth about $28,000. GAMMA Investing LLC acquired a new stake in Catalent in the 4th quarter worth about $33,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent in the 2nd quarter worth about $42,000. Finally, Mather Group LLC. acquired a new stake in Catalent in the 1st quarter worth about $52,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.